SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

ETs pullback is drawing attention amid concerns about higher interest rates and required yields for MLPs, alongside election-related uncertainty and a reported earnings miss. Traders are debating whether the weakness is an overreaction, with some buying for the distribution and long-term natural-gas demand while others worry about earnings durability and the next guidance update.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is drawing attention ahead of back-to-back clinical updates for zugo-cel and CTX310, with traders particularly focused on CTX310s Phase 1b data and its FDA RMAT designations. Optimism about the pipeline and growing CASGEVY rollout is balanced by concerns about safety, efficacy at larger scale, and whether positive data will translate into a sustained share-price move.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is drawing attention amid sharp swings in South Korean stocks, with KOSPI selloffs and trading halts linked in the discussion to weakness in AI and memory-chip shares and leveraged selling. Traders are split between treating the rebound as a buying opportunity and expecting further pressure from continued deleveraging; options activity is also described as mixed.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

A sharp pullback in the S&P 500 has prompted fears that tech-led selling and broader market weakness could deepen, with traders also citing elevated rates, inflation and geopolitical uncertainty. The community is split between warning of a bear market and treating the decline as an oversold dip-buying opportunity for long-term investors.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Rising jet-fuel costs tied to the Iran conflict and resulting pressure on Alaska Airs outlook dominate discussion, with traders weighing the earnings and guidance hit against strong travel demand and the possibility that easing oil prices could help margins. Bulls also point to international expansion, while bears warn that prolonged fuel-cost pressure could keep the shares under strain.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires Q3 results are driving discussion, with weaker operating earnings tied to insurance underwriting contrasted with record share repurchases and a large cash reserve. Traders are divided over whether the buybacks show confidence or whether soft insurance performance and limited capital deployment weigh on the outlook.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Johnson & Johnsons bleximenib data has raised concerns about future competition in frontline AML, and traders are debating whether the selloff overstates the threat. Bulls point to KOMZIFTIs commercial traction and Kuras own encouraging frontline data, while some are watching the upcoming earnings report for further evidence of launch momentum.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

Traders are focused on VXX as a hedge or short-term bet on volatility amid Iran-related geopolitical risks, oil concerns, and uncertainty about a broader market pullback. Some expect volatility to spike, while others favor shorting rallies, citing VXXs tendency to lose value as volatility cools and futures-roll costs weigh on it.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,027,969,833.918313 with 95,027,972,618.341813 in circulation. The last known price of TRON is 0.31780344 USD and is down -0.18 over the last 24 hours. It is currently trading on 1391 active market(s) with $300,352,619.62 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRONs steady price action and perceived resilience versus other cryptocurrencies dominate discussion, with traders watching for a breakout from consolidation and pointing to its stablecoin-payment activity as a bullish case. Others say the token has been stagnant or lagging and warn that the recent strength could give way to a pullback.

Litecoin (LTC) is a cryptocurrency . Users are able to generate LTC through the process of mining. Litecoin has a current supply of 84,000,000 with 77,802,148.70345862 in circulation. The last known price of Litecoin is 52.39845043 USD and is up 0.08 over the last 24 hours. It is currently trading on 1567 active market(s) with $163,649,635.32 traded over the last 24 hours. More information can be found at https://litecoin.org/.

Litecoin

Litecoin is drawing attention after retreating into the low-$50s and giving back prior gains, with traders focused on whether support will hold. Bearish commenters call the price action persistent underperformance, while bullish traders are buying the dip and looking for a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lipocine Announces Financial Results for the Third Quarter of 2026

Lipocine Announces Financial Results for the Third Quarter of 2026 Lipocine Announces Financial Results for the Third Quarter of 2026PR NewswireSALT LAKE CITY, Nov. 5, 2026 SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the...

Ardelyx (ARDX) Reports Break-Even Earnings for Q3

Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +2.55%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Add LPCN Stock to Your Portfolio Now

Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.

Nasdaq Falls Over 100 Points; US Crude Inventories Decline

U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciencesread more...

Oral Testosterone Capsule Wins Canadian Approval, Shares Up

Testosterone replacement therapy has largely relied on delivery methods that come with practical tradeoffs. Injections require needles and can cause injection-site reactions, while topical gels can be messy and carry a risk of transferring testosterone to others through skin contact. An oral treatment that does not require dose titration offers another approach in a Canadian market where more than 700,000 testosterone replacement therapy prescriptions are written annually.Shares of Lipocine Inc. (NASDAQ: LPCN) are moving higher Wednesday after the company announced that Health Canada has ...

Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy

Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement TherapyPR NewswireSALT LAKE CITY, Oct. 7, 2026SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a...

Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?

Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum DepressionPR NewswireSALT LAKE CITY, Sept. 14, 2026 Study informed by encouraging exploratory efficacy findings and a...

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SALT LAKE CITY, Sept. 10, 2026 SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty...

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Lipocine Inc

LPCN Stock Crashes 78%— Here’s Why 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile, the company said.&nbsp;</li><li>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154.</li><li>The company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward.</li></ul>Shares of Lipocine Inc. (LPCN) fell 78% on Thursday after the company said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile enough to support outpatient administration without the need for healthcare provider monitoring, the company said. No treatment-related severe or serious adverse events were reported and no cases of excessive sedation or loss of consciousness were observed, it added.<h2 class="st-heading-2">What’s Next For Lipocine?</h2>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154. The company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with postpartum depression based on the post hoc analysis results, the company said.While it waits for the FDA to get back, the company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward, including continued development of LPCN 1154, development of other product candidates, strategic transactions, partnerships, and other opportunities, it said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around LPCN rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user drew focus to the company’s remaining pipeline, which includes experimental drugs for the treatment of non-alcoholic steatohepatitis, for the management of symptoms associated with cirrhosis and another for the prevention of recurrent preterm birth.<stembedurl>https://www.stocktwits.com/Boknow/message/649308142</stembedurl>Another user expressed hopes for a minor recovery after the crash. &nbsp;<stembedurl>https://www.stocktwits.com/Ruttobillions/message/649292640</stembedurl><a href="https://stocktwits.com/symbol/LPCN">LPCN stock</a> has dropped 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sgml-stock-soars-on-100-m-bank-guarantee-retail-says-one-last-hurdle-is-behind/cZ7xCWQRI8Z">SGML Stock Soars On $100M Bank Guarantee, Retail Says 'One Last Hurdle' Is Behind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Lipocine is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.

Vanguard Total Stock Market ETF

Vanguard Extended Market ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.31	--	--	N/A
Q3 '26	-$0.35	-$0.08	77.46%	BEAT
Q2 '26	-$0.40	-$0.32	20.00%	BEAT
Q1 '26	-$0.49	-$0.54	-11.34%	MISSED
Q4 '25	-$0.61	--	--	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

LPCN Earnings

Latest Earnings Results: Q3 '26

Historical Earnings